TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Patient-centered Development of the Cancer Support Community's Open to Options ®Chatbot Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a cancer diagnosis~* Able to speak and read English, and willing to electronically consent~* Appointment with a Rogel Cancer Center cancer clinician within the next 3 weeks~* Patient must have a way to access the internet (includes mobile phone)~Exclusion Criteria:~* Age \<18 years~* Inability to speak or read English~* Inability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-Chatbot survey arm (Type: ACTIVE_COMPARATOR): Participants will take the self-appraisal survey prior to interacting with the O2O program via the online Chatbot.
- Post-Chatbot survey arm (Type: EXPERIMENTAL): Participants will take the self-appraisal survey after interacting with the O2O program via the online Chatbot. (This arm will also answer additional questions regarding participants' satisfaction with the O2O Chatbot.)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dysport in Vulvodynia Phase II Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal~* Have vulvodynia for at least 6 months and for no more than 15 years~* Have provoked pain at the vestibule on a Q tip test~Exclusion Criteria:~* Deep pain during intercourse~* Have genitourinary or gastrointestinal conditions which may interfere with the study~* Previous surgery that according to investigator's judgement may impact on study outcome (including but not limited to hysterectomy, vestibulectomy, urologic surgery, perianal surgery) or genital trauma or mutilation/cutting

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dysport - Dose Escalation stage 1 (Type: EXPERIMENTAL): Intramuscular injection of Dysport on day 1 of each cycle.
- Placebo - Dose Escalation stage 1 and Dose Expansion stage 2 (Type: PLACEBO_COMPARATOR): Intramuscular injection on day 1 of cycle 1.
- Dysport - Dose Expansion stage 2 (Type: ACTIVE_COMPARATOR): Depending upon the results from Stage 1 one or two doses of Dysport will be selected. Intramuscular injection of Dysport on day 1 of each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Heart Failure Monitoring With Eko Electronic Stethoscopes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Adults aged 18 years and older~2. Patient or patient's legal healthcare proxy consents to participation~3. Admitted to an CCU with a diagnosis of acute decompensated heart failure~4. Presence of indwelling right heart catheter~5. Receiving at least once daily hemodynamic measurements~6. Willing to have heart and lung sounds recorded with two different electronic stethoscopes~Exclusion Criteria:~1. Patient or proxy is unwilling or unable to give written informed consent~2. Patient is enrolled in another study that may interfere with the observations from this study~3. Acute pericarditis~4. Healing chest wall wounds, such as in post-sternotomy patients~5. Pacemaker (single ventricle or biventricular) with active pacing~6. Mechanical ventricular support (such as ECMO, LVAD, RVAD, BiVAD, Impella, intra-aortic balloon pumps)~7. Acute heart failure secondary to: a. Severe stenotic or regurgitant valvular disease; b. Acute myocardial infarction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: TSA Exercise Prehabilitation in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Patients scheduled for total shoulder replacement

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Aerobic Exercise Training (AET) (Type: ACTIVE_COMPARATOR): 20 sessions of AET over a 4 week period just prior to surgery
- treatment as usual (Type: NO_INTERVENTION): standard treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hepatocellular carcinoma (histology or Barcelona criteria) curatively treated by surgical resection or by radiofrequency or by cryotherapy~* Evidence of liver cirrhosis (clinical, biological, endoscopic or histological criteria)~* Morphological evaluation 4 to 6 weeks following curative treatment~* No evidence of local or distant disease on the morphological evaluation~* Absence of peritoneal or lymph node metastasis~* Absence of pre- or per-operative macroscopic tumoral thrombus~* Minimal free margin of 5 mm following pathological exam~* ALPHAAFOETOPROTEINE level of less than 4 normal values or decreased by 50%, 4 to 6 weeks following curative treatment~* Biological criteria, 2 weeks before treatment as follow:~  * neutrophilic polymorphonuclear \> 1500/mm3,~ * platelets \> 100 000/mm3,~ * total bilirubin \< 25 mmol/l (1.46 mg/dl),~ * creatinin \< 1.5 x normal value~* Eastern Cooperative Oncology Group (ECOG) equal to 0 or 1~* Life expectancy \> 12 weeks~* Absence of sensitive neuropathy at inclusion time~* Health insurance coverage~* Efficient contraceptive method if applicable~* Signed informed consent~Exclusion Criteria:~* Curative treatment performed 10 weeks or more before the beginning of adjuvant treatment~* Contraindication to an angiography or hepatic artery thrombosis or portal thrombosis.~* Pregnant or breastfeeding woman~* Concomitant involvement to any clinical trial~* Decompensate cirrhosis and Child-Pugh score ≥ 8 or clinical ascitis.~* Cancer of the Liver Italian Program (C.L.I.P.) score ≥ 2~* Heart or lung insufficiency~* Other cancer not considered as definitively cured~* Creatinin clearance \< 30 ml/min~* Recurrence of HCC less than 12 months following any last treatment~* Any radiotherapy during the 4 weeks before inclusion~* Known sensitivity to any drug of this protocol~* Immunodeficiency (HIV+, transplanted patient)~* Inability of follow up~* Impossibility of clear understanding of the protocol for no french speaking patient~* Patient under legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Oxaliplatin, gemcitabine, cisplatin, lipiodol
- 2 (Type: EXPERIMENTAL): Oxaliplatin, gemcitabine, cisplatin, lipiodol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Pulsed Electromagnetic Field Therapy for Management of Post-operative Pain Following Cesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* full term singleton pregnancy~* undergoing elective cesarean delivery~Exclusion Criteria:~* Patients who have refused, are unable to give or have withdrawn consent~* Patients unable to communicate fluently in English~* Patients with American Society of Anesthesiologists (ASA) classification of 3 or greater~* Patients with chronic pain, or neuropathic analgesic drugs~* Patients in use of antidepressant and psychotropic drugs~* Patients with a history of opioid or intravenous drug abuse~* Patients with known allergy or contra-indication to any other drugs used in this trial~* Patients who have refused spinal anesthesia, or those in whom it is contra-indicated~* Patients with a history of previous cesarean delivery and persistent pain

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Active device (Type: ACTIVE_COMPARATOR): Functional pulsed electromagnetic field device
- Placebo - inactive device (Type: PLACEBO_COMPARATOR): Inactive pulsed electromagnetic field device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Multiple Oncological Serial Scans Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~All female patients who, after breast conserving surgery, are to undergo whole breast irradiation with or without a boost. Ten patients will be for planned radiotherapy following both breast conservation surgery and chemotherapy and ten will be for planned radiotherapy following breast conservation surgery alone aged between 18 and 80years.~-~Exclusion Criteria:~Mastectomy T3 or T4 and N3 cases Patients who have not undergone surgery Severely claustrophobic patients Patients unable to lie flat Patients with any contraindications to MRI~-

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: In Vivo Alzheimer Proteomics

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Reports written consent, informed and signed by the patient and a trusted person~* Subject member or beneficiary of a social security system~Specific criteria for group 1 and 2B :~* Age between 55 and 85 years old for patients~* Subject with AD or other neurodegenerative disease (frontotemporal dementia, dementia with Lewy bodies, Parkinson disease)~* Subjects with chronic adult hydrocephalus (HCA) requiring depletion lumbar puncture (PL)~Specific criteria for group 2A :~- Adult patient requiring neurosurgery with CSF shunt (subject with brain trauma, acute hydrocephaly) and favorable evolution that allows removal of the shunt~Exclusion Criteria:~* Patient deprived of liberty by judicial or administrative decision~* Major protected by law~* Pregnancy, women of childbearing age with risk of pregnancy, or breast-feeding~* Presence of a transmissible viral disease (HlV, hepatitis B and C)~* Patient included in a clinical trial~* lnadequate cardiac, hepatic or severe renal disfunction~* Disease amino acid metabolism (Leucinose..)~Exclusion Criteria:~* Information clinical and para-clinical insufficient or unavailable~* Patient deprived of liberty by judicial or administrative decision~* Major protected by law~* Pregnancy, women of childbearing age with risk of pregnancy, or breast~* feeding~* Presence of a transmissible viral disease (HIV, hepatitis B and C)~* Patient included in a clinical trial~* Patient exclusion period relative to another protocol or for which the maximum annual compensation of 4500€ has been reached~* Inadequate cardiac, hepatic or severe renal~* Disease amino acid metabolism (Leucinose..)

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): 60 patients (20 probable AD, 20 Parkinson Disease (PK), 20 neurological disease without cognitive degradation)
- Group 2A (Type: EXPERIMENTAL): 20 patients (patients with brain trauma, acute hydrocephaly), with temporary derivation of the CSF
- Group 2B (Type: EXPERIMENTAL): 30 patients (15 probable AD, 15 neurological disease without cognitive degradation)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following Dental Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have at least 10 teeth~* Subjects must have the need for a dental extraction under general anesthesia (for behavioral reasons)~* Subjects will be recruited regardless of the extent and severity of their dental and/or periodontal disease~Exclusion Criteria:~* Age under 18 years~* Body weight under 40 kg~* Receipt of antibiotics in the previous 3 months~* Routine use of oral antiseptics~* A history of allergy or intolerance to amoxicillin~* A history of allergy or intolerance to chlorhexidine~* A history of allergy or intolerance to amoxicillin-clavulanate~* Any type of congenital or acquired immunodeficiency~* Any known risk factor for bacterial endocarditis~* Any known risk factor for prolonged bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Receiving no prophylaxis
- Amoxicillin (Type: ACTIVE_COMPARATOR): Receiving 2 gr oral Amoxicillin before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin
- Amoxicillin-Potassium Clavulanate (Type: EXPERIMENTAL): Receiving 2gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation~Intervention: Drug: Amoxicillin-Potassium Clavulanate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Contribution of Auriculotherapy in the Management of Mastectomy With Immediate Reconstruction by Latissimus Dorsi Flap (ATMAGD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women patient over 18 years-old~* Patient scheduled for a mastectomy with immediate reconstruction by latissimus dorsi flap with or without symmetrization on the contralateral breast.~* Patient affiliated or beneficiary of a social security scheme.~* Patient who has given her free and informed consent.~* Preoperative blood test showing no contraindication to the operation.~Exclusion Criteria:~* Refusal of the patient.~* No indication for auriculotherapy:~* Patient having a heavy treatment with neuroleptics,~* Or tricyclic antidepressants which interfere with the action of auriculotherapy.~* Patient undergoing long-term morphine treatment for chronic pain.~* Patient with unweaned opioid addiction.~* Chronic painful patient.~* Protected patient: Major under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision; Hospitalized without consent.~* Pregnant, breastfeeding or parturient woman.~* Patient participating in another interventional study.~* Patient who had already participated in this study as part of first breast surgery.~* Patient receiving regular care by auriculotherapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with auriculotherapy (Type: EXPERIMENTAL): Mastectomy operated patient then, auriculotherapy
- Patient with placebo (Type: PLACEBO_COMPARATOR): Mastectomy operated patient then, they received placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Steroids on Post-Operative Complications Following Proximal Hypospadias Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing proximal hypospadias repair~Exclusion Criteria:~* All patients currently taking steroids at the time of surgery or during the six-week recovery period as well as patients with betamethasone hypersensitivity will be excluded from the study. Selection will be based on parent willingness to allow the child to participate in the study.

- Gender: MALE
- Minimum Age: 3 Months
- Maximum Age: 22 Years
- Healthy Volunteers: t

Study Arms:
- oral steroids (Type: ACTIVE_COMPARATOR): Systemic high-dose steroids (30 mg/kg methylprednisolone) have been shown in a randomized, double-blind, placebo-controlled trial in humans not to negatively impact wound infection or dehiscence rates, instead benefitting patients in the postoperative period in ways such as decreasing pain. An acute course of oral systemic steroids has been routinely used in patients under the age of 12 with asthma exacerbations (liquid prednisolone at 1-2 mg/kg/day in 1-2 divided doses for up to 10 days, although usually given for 5 days, which is at least 19 times less than the dose proven to be safe in the randomized controlled trial mentioned above) and proven to be safe without adverse effects. Effect of prednisolone on the systemic response and wound healing after colonic surgery.
- placebo-controlled (Type: PLACEBO_COMPARATOR): Simple Syrup will be used as the placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment With Autologous Skeletal Myoblasts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a diagnosis of coronary disease obtained by coronary angiography who require conventional aortocoronary bypass surgery.~* History of myocardial infarction with evidence of regional akinesis (or dyskinesia) for more than 4 weeks and less than 10 years.~* Ejection fraction from 25% to 45%.~* Evidence of no regional viability by dobutamine echocardiography.~* Aged from 30-80 years old.~* Negative serology to HIV, HBV and HCV.~* Patients without organ dysfunction.~* Negative pregnancy test (women of childbearing age).~* Informed consent granted.~Exclusion Criteria:~* History of myocardial infarction in the 4 weeks prior to the inclusion in the study.~* Prior history of tachycardia or ventricular fibrillation (except in patients with DAI device).~* History of cancer (except basocellular carcinoma) or prior treatment with chemotherapy.~* The patient should not suffer from any concomitant severe and/or uncontrolled medical condition.~* Patients who, due to their geographical, psychiatric or social status, have difficulties in meeting the conditions established in the protocol.~* Pregnant or beast feeding women.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Skeletal myoblasts (Type: EXPERIMENTAL): Patients who are receiving skeletal myoblasts
- Placebo (Type: PLACEBO_COMPARATOR): Revascularisation surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Liver biopsy acceptation~* B hepatitis grade over or equal to F2 Metavir score~* DNA HBV greater than 100000 copies/mL (or 10000 copies/mL if Ag Hbe negative)~* ALAT greater than 1.3 times the upper normal limit~Exclusion Criteria:~* HCV, HDV and HIV positive~* Pregnancy~* Decompensated liver cirrhosis~* Pretreated patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Lamivudine alone
- 2 (Type: EXPERIMENTAL): Lamivudine + Vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues